| Followers | 2528 |
| Posts | 250766 |
| Boards Moderated | 33 |
| Alias Born | 05/06/2014 |
Wednesday, April 29, 2020 12:11:21 PM
$PMCB Pharmacyte Inc (PMCB) has exercised acute failure of internal controls and procedures per executive compensation.
As described on page 83 of the last 10K, the nominating compensation committee consists of 3 BOD members: Dr. Crabtree, Dr. Tong and Mr. Liquard. They in turn have nominated 3 BOD members to comprise the compensation committee: Mr. Liquard, Mr. Waggoner and Mr. Yuen. Note also the audit committee consists of 4 members, of which 3 are BOD members: Dr. Michael Abecassis, Dr. Tong, Mr. Yuen and Mr. Thomas.
Attached on page 94 of the last 10K is a copy of the corporate bylaws.
In Article IV it is stated annual Share Holder meetings will be held on 05-Mar. Under Article II section 4 of the bylaws, Shareholders will vote to elect 3 Board of Directors.
Prior to 11-Sep-19, no annual Shareholder meeting had been held.
Therefore, all current BOD members were appointed by other BOD members prior to 11-Sep-19, without a vote by Shareholders, in direct violation of the corporate bylaws.
Therefore, the members of both the Nominating Compensation Committee, and those that comprise the Compensation Committee were illegally placed in such corporate capacities.
Therefore, all past compensation granted prior to 11-Sep-19 was granted illegally.
Therefore, 3 out of 4 members of the Audit committee also are illegal. Demonstrating a lack of auditing internal controls.
Therefore, all of the Certifications attached to the 10K are fraudulent.
https://ih.advfn.com/stock-market/USOTC/pharmacyte-biotech-inc-PMCB/stock-news/80526109/annual-report-10-k
As described on page 83 of the last 10K, the nominating compensation committee consists of 3 BOD members: Dr. Crabtree, Dr. Tong and Mr. Liquard. They in turn have nominated 3 BOD members to comprise the compensation committee: Mr. Liquard, Mr. Waggoner and Mr. Yuen. Note also the audit committee consists of 4 members, of which 3 are BOD members: Dr. Michael Abecassis, Dr. Tong, Mr. Yuen and Mr. Thomas.
Attached on page 94 of the last 10K is a copy of the corporate bylaws.
In Article IV it is stated annual Share Holder meetings will be held on 05-Mar. Under Article II section 4 of the bylaws, Shareholders will vote to elect 3 Board of Directors.
Prior to 11-Sep-19, no annual Shareholder meeting had been held.
Therefore, all current BOD members were appointed by other BOD members prior to 11-Sep-19, without a vote by Shareholders, in direct violation of the corporate bylaws.
Therefore, the members of both the Nominating Compensation Committee, and those that comprise the Compensation Committee were illegally placed in such corporate capacities.
Therefore, all past compensation granted prior to 11-Sep-19 was granted illegally.
Therefore, 3 out of 4 members of the Audit committee also are illegal. Demonstrating a lack of auditing internal controls.
Therefore, all of the Certifications attached to the 10K are fraudulent.
https://ih.advfn.com/stock-market/USOTC/pharmacyte-biotech-inc-PMCB/stock-news/80526109/annual-report-10-k
Recent PMCB News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:17:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 10:16:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:19:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/17/2026 07:49:54 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/09/2026 01:40:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 10:02:46 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/27/2026 10:05:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/07/2026 10:43:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 12/18/2025 10:04:23 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 12/15/2025 09:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/12/2025 10:07:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2025 10:00:25 PM
- PharmaCyte Biotech stock surges following profitable exit from Femasys investment • IH Market News • 11/25/2025 03:56:47 PM
- PharmaCyte Biotech Successfully Monetizes Femasys Stake, Strengthening Cash Position and Underscoring Strategic Capital Deployment • Business Wire • 11/25/2025 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:32:29 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/18/2025 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 08:05:33 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/06/2025 09:08:43 PM

